Report Content
Chapter 1 Methodology & Scope
1.1 Industry coverage
1.2 Market scope & definitions
1.3 Base estimates & working
1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Rare disease treatment industry 3600 synopsis, 2018-2032
2.1.1 Business trends
2.1.2 Drug type trends
2.1.3 Therapeutic area trends
2.1.4 Patient trends
2.1.5 Route of administration trends
2.1.6 Regional trends
Chapter 3 Rare Disease Treatment Industry Insights
3.1 Industry landscape, 2018 – 2032
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increase in the prevalence of rare diseases
3.2.1.2 Favourable government policies
3.2.1.3 Growing number of new drug launches
3.2.1.4 Increasing R&D activities for novel therapeutics and drugs
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of awareness regarding rare disease treatment
3.2.2.2 High cost of the drugs and therapy
3.3 Growth potential analysis
3.3.1 By drug type
3.3.2 By therapeutic area
3.3.3 By patient
3.3.4 By route of administration
3.4 COVID- 19 impact analysis
3.5 Clinical trials scenario for rare disease treatment
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.6.3 Asia Pacific
3.7 Pipeline analysis
3.8 Future market trends
3.9 Technology landscape
3.10 Vendor matrix analysis
3.11 Epidemiology scenario
3.12 Current therapies
3.13 Reimbursement scenario
3.13.1 North America
3.13.2 Europe
3.13.3 Asia Pacific
3.13.4 Latin America
3.13.5 MEA
3.14 Porter's analysis
3.15 PESTEL analysis
Chapter 4 Competitive Landscape, 2021
4.1 Introduction
4.2 Company matrix analysis, 2021
4.3 Competitive analysis of major market players
4.4 Competitive Positioning matrix
4.5 Company market share
4.6 Strategy dashboard, 2021
Chapter 5 Rare Disease Treatment Market, By Drug Type
5.1 Key drug type trends
5.2 Biologics
5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Non-biologics
5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Rare Disease Treatment Market, By Therapeutic Area
6.1 Key therapeutic area trends
6.2 Cancer
6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Blood-related Disorders
6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4 Central Nervous System (CNS)
6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.5 Respiratory Disorders
6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.6 Musculoskeletal Disorders
6.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.7 Cardiovascular Disorders
6.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.8 Others
6.8.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Rare Disease Treatment Market, By Patient
7.1 Key patient trends
7.2 Adult
7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.3 Pediatric
7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 8 Rare Disease Treatment Market, By Route of Administration
8.1 Key route of administration trends
8.2 Oral
8.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.3 Injectable
8.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 9 Rare Disease Treatment Market, By Region
9.1 Key regional trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Poland
9.3.7 Switzerland
9.3.8 Sweden
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Indonesia
9.4.7 Thailand
9.4.8 Vietnam
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Chile
9.5.5 Colombia
9.5.6 Peru
9.6 MEA
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Israel
9.6.5 Iran
9.6.6 Egypt
Chapter 10 Company Profiles
10.1 AbbVie Inc
10.2 Seagen Inc.
10.3 AstraZeneca plc
10.4 Alexion Pharmaceuticals, Inc
10.5 Amgen Inc
10.6 Baxter International
10.7 Bayer AG
10.8 Biogen
10.9 Bristol-Myers Squibb
10.10 Eli Lilly and Company
10.11 Hoffman-La-Roche
10.12 GlaxoSmithKline plc
10.13 Johnson & Johnson
10.14 Merck & Co Inc.
10.15 Novartis AG
10.16 Novo Nordisk
10.17 Pfizer Inc.
10.18 Pharmacyclics LLC
10.19 Sanofi SA
10.20 Seagen Inc.
10.21 Takeda Pharmaceutical Company Limited
10.22 Vertex Pharmaceuticals Incorporated